Adagio Therapeutics Inc

-2.11 (-5.90%)
Earnings Announcements

Adagio Therapeutics Q2 Loss Per Share $0.18, To Present COVID-19 Antibody Program Data At IDWeek 2021

Published: 09/20/2021 10:51 GMT
Adagio Therapeutics Inc (ADGI) - Adagio Therapeutics Provides Covid-19 Antibody Program Updates As Well As Business Highlights and Second Quarter 2021 Financial Results.
New Data Supporting Potential of Adg20 for Both Treatment and Prevention of Covid-19 to Be Presented at Idweek 2021.
Adagio - Data Support Evaluation of 300mg Dose, Delivered As Single Intramuscular Injection, in Ongoing Phase 2/3 Stamp & Evade Global Clinical Trials.
Q2 Loss per Share 0.18 Usd.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.67

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.14

More details on our Analysts Page.